此外，2025年登陆A股的江苏企业，常州有2家，分别是3月4日上市的常友科技和5月16日上市的泽润新能，无锡、南通、淮 安、扬州、镇江、泰州各有1家。 新苏商了解到，今年上半年共有51家企业在A股成功IPO，江苏占比约23.53%，数量位列全国第一。 2025年已经过半。回顾上半年，江苏共有12家企业成功登陆A股，IPO数量领先全国。此外，还有6家企业成功登陆港股。具体 来看，哪个城市上市公司数量领跑全省？江苏上市后备力量如何？新苏商进行了梳理和盘点。 | 证券简称 | 上市时间 | 墓资金额(亿元) | 所属域市 | 最新市值(亿元) | | --- | --- | --- | --- | --- | | 塞分科技 | 1月10日 | 2.16 | 苏州 | 69.67 | | 惠通科技 | 1月15日 | 4.14 | 扬州 | 47.95 | | 常友科技 | 3月4日 | 3.2 | 常州 | 32.04 | | 胜科纳米 | 3月25日 | 3.66 | 苏州 | 107.12 | | 泰禾股份 | 4月11日 | 4.62 | ■商 | 140.45 | | 江顺科技 | 4月24日 | 5.6 ...

导读： 2025年7月，将有714份新标准正式实施，其中色谱质谱分析、光谱分析、环境监测等仪器技术成为高频关键词。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 714 份标准将于7月份实施 ——《液相色谱法术语》等迎来更新 科学仪器作为现代工业与科研的"眼睛"和"双手"，其应用广度与深度直接决定了各行业的技术水平与发展速度。 高效液相色谱（HPLC）与气相色谱-质谱联用（GC-MS）技术成为食品安全的核心保障。例如，《GB/T 45139-2024 》通过HPLC精准 测定香柠檬精油中的有害成分，而《SN/T 5719-2024 》等标准则对食品接触材料的迁移物进行分析，确保"舌尖上的安全"。 编织生态监测网络： 环境治理依赖高灵敏度检测技术。新实施的《HJ 1399 - 2024 》采用三重四极杆质谱法测定水中17种抗生素残留，灵敏度达纳克级；《HJ 139 2 - 2024 》等则通过色谱质谱来追踪大气中的氨和硫化氢等污染情况。 仪器赋能工业升级 ： 术语标准化：《GB/T 9008-2024液相色谱法术语 》迎来更新 在钢铁、汽车 ...

Core Viewpoint - Nanwei Technology is positioned as a leading company in high-performance nano microsphere materials, with significant improvements in performance margins and growth opportunities in the chromatography filler sector due to import substitution and commercialization expansion [2][3][6]. Company Overview - Established in 2007, Nanwei Technology specializes in the R&D, mass production, sales, and application services of high-performance nano microsphere materials for various sectors including biomedicine and diagnostics [2]. - The company faced growth pressures in 2023 due to external macroeconomic changes, but has shown significant performance recovery since Q4 2024, with a quarterly revenue of 233 million yuan, a year-on-year increase of 71.47%, and a net profit of 41 million yuan, up 38.05% [2]. Market Opportunities - The global chromatography media market is projected to grow from 6.9 billion USD in 2023 to 9 billion USD by 2026, with a compound annual growth rate (CAGR) of 9.26%. The Chinese market is expected to grow from 11.2 billion yuan to 20.3 billion yuan in the same period, with a CAGR of 21.92% [3]. - Nanwei Technology is well-positioned to benefit from two major opportunities: import substitution and commercialization expansion. The company has developed a comprehensive range of chromatography fillers and media, making it a key player in the domestic market [3][4]. Import Substitution Opportunity - The chromatography filler and media industry has been historically dominated by foreign companies, with low domestic production rates. The rapid development of the domestic biomedicine industry and geopolitical tensions are driving the need for local alternatives [3]. - Successful project changes by downstream client Heng Rui Pharmaceutical provide a template for future import substitution projects, positioning Nanwei Technology as a leader in this transition [3]. Commercialization Expansion Opportunity - The usage of chromatography fillers and media increases with project phases, from early clinical trials to commercialization. Nanwei Technology has accumulated a growing number of clients and is nurturing numerous mid-to-late clinical projects, which are expected to yield significant returns [4]. Industry Chain Layout - Beyond its core business, Nanwei Technology is expanding its industry chain through a combination of self-built and acquired entities, including subsidiaries focused on chromatography instruments and diagnostic materials [5]. - Key subsidiaries include: - Fuli Instruments, a leader in domestic chromatography instruments, has made strides in gas and liquid chromatography [5]. - NAP Analysis, which focuses on high-quality laboratory chromatography consumables, achieving full domestic production [5]. - Saip Instrument, which develops precision purification equipment for large biomolecules, establishing itself as a leader in the domestic market [5]. Financial Forecast - Revenue projections for Nanwei Technology are 1 billion yuan in 2025, 1.24 billion yuan in 2026, and 1.55 billion yuan in 2027, with corresponding net profits of 141 million yuan, 221 million yuan, and 285 million yuan [6]. - The company is expected to maintain a strong growth trajectory, supported by its leadership in the chromatography filler and media sector and its strategic industry chain expansions [6].

色谱填料主业把握两大机遇，全产业链布局打开成长天花板 [Table_CoverStock] —纳微科技(688690)公司深度报告 [Table_ReportDate] 2025 年 06 月 06 日 [Table_CoverAuthor] 唐爱金 医药行业首席分析师 贺鑫 医药行业分析师 S1500523080002 S1500524120003 tangaijin@cindasc.com hexin1@cindasc.com [Table_StockAndRank] 纳微科技(688690) [Table_CoverReportList] 证券研究报告 公司研究 [Table_ReportType] 公司深度报告 投资评级 买入 [Table_Chart] 资料来源：聚源，信达证券研发中心 [Table_BaseData] 公司主要数据 收盘价（元） 21.80 52 周内股价波动区间 (元) 24.12-13.38 最近一月涨跌幅(％) -2.50% 总股本(亿股) 4.04 流通 A 股比例(％) 100% 总市值(亿元) 88.03 -40% -20% 0% 20% 40% 24/06 24/10 ...

色谱填料主业把握两大机遇，全产业链布局打开成长天花板 [Table_CoverStock] —纳微科技(688690)公司深度报告 [Table_ReportDate] 2025 年 06 月 06 日 [Table_CoverAuthor] 唐爱金 医药行业首席分析师 贺鑫 医药行业分析师 S1500523080002 S1500524120003 tangaijin@cindasc.com hexin1@cindasc.com [Table_CoverReportList] 证券研究报告 公司研究 [Table_ReportType] 公司深度报告 [Table_StockAndRank] 纳微科技(688690) 投资评级 买入 [Table_Chart] 资料来源：聚源，信达证券研发中心 [Table_BaseData] 公司主要数据 收盘价（元） 21.80 52 周内股价波动区间 (元) 24.12-13.38 最近一月涨跌幅(％) -2.50% 总股本(亿股) 4.04 流通 A 股比例(％) 100% 总市值(亿元) 88.03 -40% -20% 0% 20% 40% 24/06 24/10 ...

Core Viewpoint - The ion chromatography industry in China has made significant advancements since the development of the first domestic ion chromatograph in 1983, with a projected market size of 3.936 billion yuan in 2024, reflecting a year-on-year increase of 12.33% [1][16]. Industry Overview - Ion chromatography is a high-efficiency liquid chromatography instrument used for analyzing cations and anions in aqueous solutions, relying on ion exchange resin for separation [3]. - The main types of ion chromatography include ion exchange chromatography, ion exclusion chromatography, and ion pair chromatography, with ion exchange chromatography being the most widely used [3]. Industry Chain - The upstream of the ion chromatography industry includes raw materials and component supply, while the midstream involves the manufacturing of ion chromatographs. The downstream applications span environmental monitoring, food analysis, agriculture, medicine, and pharmaceuticals [7]. Market Demand and Growth - The demand for ion chromatography is driven by its applications in environmental monitoring, food safety, and pharmaceuticals, with the global market size reaching $2.97 billion in 2023 and expected to grow to $3.72 billion by 2029 [14]. - In China, the environmental monitoring industry is projected to grow to 47.825 billion yuan in 2024, while the food safety testing market is expected to reach 16.99 billion yuan, both reflecting significant year-on-year growth [9][11]. Competitive Landscape - The ion chromatography market is characterized by high concentration, with top companies like Thermo Fisher, Qingdao Shenghan, and others accounting for 88% of the total bid amount in 2024. Domestic brands are gaining market share, contributing over 30% to the market [20][22]. - In 2024, over 600 ion chromatography projects were reported, with a total bid amount exceeding 350 million yuan, indicating a competitive landscape where domestic brands are rapidly penetrating the market [18]. Development Trends - The industry is moving towards miniaturization and portability to enhance field testing capabilities, allowing for rapid response to water quality incidents [28]. - There is a trend towards integrating multi-dimensional separation technologies to improve separation efficiency and resolution [29]. - The level of automation and intelligence in ion chromatography is increasing, with advancements in automated sample injection and data analysis systems [30][31].

导读： 5月12日，ACCSI 2025色谱新应用场景及产业生态升级发展论坛成功举办，围绕色谱技术的最新进展、国产化发展路径以及产 业生态的协同升级展开了深度研讨，现场超150人参会，气氛热烈，座无虚席。 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 2025年5月12日，由仪器信息网主办的第十八届中国科学仪器发展年会(ACCSI 2025)在上海松江盛大开幕，吸引超 1800位科学仪器行业相关政府领导、院士专家、领域专家学者、科学仪器企业、投资人等参会，会议规模再创新高。 色谱新应用场景及产业生态升级发展论坛作为本届大会的重要分论坛之一，其以"聚焦细分市场突围，解码色谱行业新 机遇"为主题，围绕色谱技术的最新进展、国产化发展路径以及产业生态的协同升级展开了深度研讨。 论坛由色谱领域权威专家——北京大学刘虎威教授与复旦大学张祥民教授联合主持，吸引了来自科研院所、高等院校、 仪器厂商、零部件供应商等领域的专家学者及行业代表逾150人齐聚一堂，现场气氛热烈，座无虚席。 北京大学刘虎威教授（左）和复旦大学张祥民教授（右）共同主持会议 报 ...

汉邦科技董事长、总经理 张大兵 ◎钱佳滢 记者 仲茜 5月16日，主营色谱仪设备与耗材研发、生产、销售的汉邦科技在科创板挂牌，成为科创板液相色谱装 备第一股。 从色谱耗材代理商到国产制备色谱龙头，汉邦科技用26年时间"比学赶超"，成为国内制药、生命科学等 领域分离纯化技术的"隐形冠军"。近日，汉邦科技董事长、总经理张大兵在接受上海证券报记者专访时 表示，公司已掌握了具有汉邦特色的"一心两核多用"色谱技术，接下来将围绕色谱系统集成、色谱应用 两大核心技术，以被誉为色谱"心脏"的色谱柱技术为锚点，不断探索色谱技术在工业生产、实验室研发 等场景中的应用，努力打造国际色谱行业第一品牌。 科技破壁：从代理贸易到自主研发 色谱仪是一种用于分离和分析混合物中各成分的仪器，是现代药学发展的重要工具。色谱仪的精密度， 直接影响药物作用评价的准确度。 1998年，汉邦科技在江苏淮阴成立，以代理色谱系列耗材起家。"最初我们做的是实验室色谱试剂、色 谱柱的代理销售和生产，头两年还处于卖方市场，利润比较正常，但到2006年左右，做这块业务的人逐 渐就多了，到后来连化工商店都可以做。"张大兵对记者谈起公司创立初期的经历。 发展遇到瓶颈， ...

导读： 华谱科仪完成过亿元Pre-B轮融资，致力于推进国产液相色谱技术革新与应用，打破进口垄断局面。 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日，国产色谱设备、软件和耗材全体系平台企业 华谱科仪（北京）科技有限公司（以下简称"华谱科仪"） 已完成过 亿元 Pr e -B轮融资，本轮融资由京国瑞基金和北工投资在管的北京高精尖基金共同领投，老股东弘晖基金、架桥资本 跟投 ，本轮所融资金将主要用于国内外销售渠道的进一步建设和下一代产品的开发。 长海资本持续担任公司融资的独 家财务顾问 。 自2 0 1 5年成立以来，华谱科仪已建立起HPLC（高效液相色谱仪）、UHPLC（超高效液相色谱仪）以及配套的软件和 对应耗材的一系列产品矩阵。目前公司自有品牌仪器在色谱主流应用市场保有量达到数千台。华谱科仪凭借成熟完备的 合规化软件系统与服务体系，在国产液相色谱领域构建起显著的竞争优势，是行业内为数不多可以成体量进入海关、质 检、药监等制标单位，以及药企、CRO企业等关键商业化客户的厂商。 在现有产品以外，华谱科仪还在不断地拓展产品矩阵，从 ...

IPO Review and Registration Progress - Ningbo Jianxin Superconducting Technology Co., Ltd. has received acceptance for its IPO application on the Sci-Tech Innovation Board, marking the third new acceptance this year [2] - The company reported revenues of 359 million yuan, 451 million yuan, and 425 million yuan for 2022 to 2024, with net profits of 34.63 million yuan, 48.73 million yuan, and 55.78 million yuan respectively [2] - The company plans to raise 865 million yuan through its IPO for projects including the production of superconducting magnets and working capital [3] - Lianchuan Biotechnology has also received acceptance for its IPO on the Beijing Stock Exchange, aiming to raise 300 million yuan for projects related to gene technology and working capital [4] - The company reported revenues of 234 million yuan, 287 million yuan, and 367 million yuan from 2022 to 2024, with net profits of 52.76 million yuan, 53.49 million yuan, and 60.06 million yuan respectively [4] - Dana Biotechnology submitted its IPO registration on the Beijing Stock Exchange, focusing on early rapid diagnostic technology for invasive fungal diseases [6] - Han Gao Group's IPO registration has been approved, with projected revenues of 2.857 billion yuan and net profits of 531 million yuan for 2024 [6] New Stock Subscription and Listing Dynamics - Three new stocks are scheduled for subscription this week, including Hanbang Technology, Weigao Blood Purification, and Taili Technology [8] - Hanbang Technology aims to raise 598 million yuan for the production of liquid chromatography equipment, with projected revenues of 691 million yuan and net profits of 79 million yuan for 2024 [8] - Weigao Blood Purification plans to raise 1.351 billion yuan for smart production and other projects, with sales expenses exceeding 600 million yuan from 2022 to 2024 [9] - Taili Technology focuses on new materials and plans to raise 542 million yuan for production and logistics center construction, with projected revenues of 1.02 billion yuan and net profits of 88 million yuan for 2024 [9] Upcoming Listings - Tian Gong Co., Ltd. is set to be listed on the Beijing Stock Exchange on May 13, with projected revenues of 383 million yuan, 1.035 billion yuan, and 801 million yuan from 2022 to 2024 [11] - The company plans to raise 360 million yuan for the construction of high-end titanium and titanium alloy production lines [11] Policy and Regulatory Trends - The China Securities Regulatory Commission (CSRC) plans to introduce policies to deepen reforms in the Sci-Tech Innovation Board and the Growth Enterprise Market, enhancing the system's inclusiveness and adaptability [12]